Showing results (1871-1880 of 1,933) with videos related to
Sort By:
Pageof 194
European Journal of Cancer (Oxford, England : 1990)|April 6, 2023
Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignanciesOlivier J Van Not, Alfons J M van den Eertwegh, John B Haanen, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 27, 2023
Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the NetherlandsMichiel C T van Zeijl, Jesper van Breeschoten, Liesbeth C de Wreede, et al.BMC Cancer|May 23, 2024
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocolJ C Janssen, B van Dijk, K de Joode, et al.Cancers|December 11, 2019
Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?Maartje G Schouwenburg, Karijn P M Suijkerbuijk, Rutger H T Koornstra, et al.Blood|March 5, 2020
MKL1 deficiency results in a severe neutrophil motility defect due to impaired actin polymerizationEvelien G G Sprenkeler, Stefanie S V Henriet, Anton T J Tool, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment RegistryRik J Verheijden, Anne M May, Christian U Blank, et al.JAMA Oncology|October 27, 2022
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced MelanomaOlivier J van Not, Rik J Verheijden, Alfonsus J M van den Eertwegh, et al.Pigment Cell & Melanoma Research|August 9, 2023
Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohortJ S W Borgers, F H Burgers, A Schina, et al.Cancers|April 25, 2020
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted DrugsBrenda Leeneman, Carin A Uyl-de Groot, Maureen J B Aarts, et al.International Journal of Cancer|June 20, 2020
Real-world outcomes of advanced melanoma patients not represented in phase III trialsMichiel C T van Zeijl, Rawa K Ismail, Liesbeth C de Wreede, et al.Pageof 194